https://orcid.org/0000-0001-5142-8355
Figures
Abstract
Background
Sexually transmitted and genital infections in pregnancy are associated with adverse pregnancy and birth outcomes. Point-of-care tests for these infections facilitate testing and treatment in a single antenatal clinic visit and may reduce the risk of adverse outcomes. Successful implementation and scale-up depends on understanding comparative effectiveness of such programmes and their comparative costs and cost effectiveness. This systematic review synthesises and appraises evidence from economic evaluations of point-of-care testing and treatment for sexually transmitted and genital infections among pregnant women in low- and middle-income countries.
Methods
Medline, Embase and Web of Science databases were comprehensively searched using pre-determined criteria. Additional literature was identified by searching Google Scholar and the bibliographies of all included studies. Economic evaluations were eligible if they were set in low- and middle-income countries and assessed antenatal point-of-care testing and treatment for syphilis, chlamydia, gonorrhoea, trichomoniasis, and/or bacterial vaginosis. Studies were analysed using narrative synthesis. Methodological and reporting standards were assessed using two published checklists.
Results
Sixteen economic evaluations were included in this review; ten based in Africa, three in Latin and South America and three were cross-continent comparisons. Fifteen studies assessed point-of-care testing and treatment for syphilis, while one evaluated chlamydia. Key drivers of cost and cost-effectiveness included disease prevalence; test, treatment, and staff costs; test sensitivity and specificity; and screening and treatment coverage. All studies met 75% or more of the criteria of the Drummond Checklist and 60% of the Consolidated Health Economics Evaluation Reporting Standards.
Conclusions
Generally, point-of-care testing and treatment was cost-effective compared to no screening, syndromic management, and laboratory-based testing. Future economic evaluations should consider other common infections, and their lifetime impact on mothers and babies. Complementary affordability and equity analyses would strengthen the case for greater investment in antenatal point-of-care testing and treatment for sexually transmitted and genital infections.
Citation: Saweri OPM, Batura N, Al Adawiyah R, Causer LM, Pomat WS, Vallely AJ, et al. (2021) Economic evaluation of point-of-care testing and treatment for sexually transmitted and genital infections in pregnancy in low- and middle-income countries: A systematic review. PLoS ONE 16(6): e0253135. https://doi.org/10.1371/journal.pone.0253135
Editor: Remco PH Peters, University of Pretoria, SOUTH AFRICA
Received: October 8, 2020; Accepted: May 30, 2021; Published: June 17, 2021
Copyright: © 2021 Saweri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: WANTAIM is a partnership of academic and governmental institutions in Papua New Guinea, Australia and Europe. The trial is funded by a Joint Global Health Trials award from the UK Department for International Development, the UK Medical Research Council and the Wellcome Trust (MR/N006089/1); a Project Grant from the Australian National Health and Medical Research Council (GNT1084429); and a Research for Development award from the Swiss National Science Foundation (IZ07Z0_160909/1). OPMS and RA are supported by The University of New South Wales Scientia Higher Degree Candidate Scholarship Scheme. All authors’ affiliated institutions contributed via facilities and/or salary contributions. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have no competing interests.
Abbreviation list: BV, bacterial vaginosis; CHEERS, consolidated health economic evaluation reporting standard; CT, chlamydia; DALYs, disability-adjusted-life-years; dRDT, dual rapid diagnostic test for HIV and syphilis; dRST, dual rapid syphilis test to determine Treponema and non-Treponema infections; HIV, human immunodeficiency virus; hRDT, point-of-care test for HIV; IEC, Information/Education/ Communication; LMIC, low- and middle- income countries; MDA, mass drug administration; NG, gonorrhoea; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RPR, repaid plasma regain test; RST, rapid syphilis test; STI, sexually transmitted and genital infection; TPHA test, Treponema pallidum haemagglutination assay test; TV, Trichomoniasis
Introduction
Sexually transmitted and genital infections (henceforth, referred to as STIs) during pregnancy are associated with a number of adverse pregnancy and birth outcomes [1–9] and their burden is highest in low- and middle- income countries (LMICs) [10–12]. Among the most prevalent infections are the curable STIs: syphilis, gonorrhoea (NG), chlamydia (CT), trichomoniasis (TV) and bacterial vaginosis (BV) [13, 14]. Untreated STIs in pregnancy can be associated with miscarriage, pre-term birth, stillbirth, low birth weight and neonatal eye and respiratory infections [15, 16].
Evidence shows that early detection and treatment of HIV and syphilis during pregnancy reduces the risk of adverse pregnancy and birth outcomes [17–20]. The World Health Organization (WHO) currently recommends HIV and syphilis testing for all pregnant women attending antenatal clinics [21–23]. The recommendation is driven by the commitment to eliminate the mother-to-child-transmission of HIV and syphilis [24]. Effective screening programs in antenatal clinics therefore play a pertinent role in ensuring early detection and treatment of HIV and syphilis, which directly improve maternal and child health.
Interventions utilised for diagnosing and/or treating STIs are illustrated in Table 1. For more than two decades, the diagnosis of STIs in many LMIC settings has been based on the WHO-endorsed strategy of syndromic management i.e. clinical diagnosis with no laboratory confirmation [25]. Syndromic management is often inaccurate and misses asymptomatic infections that make up a significant proportion of STIs in women [26, 27]. Laboratory-based diagnosis is beyond the reach of many health services in LMICs due to technical requirements and costs and even where it is available, delays in testing and the provision of results often prevent the timely initiation of treatment [28–31].
Technological advancements and the drive to find diagnostic solutions suitable for use at point-of-care have led to the development of a number of accurate, portable, simple-to-use and low- cost tests that are reshaping the global landscape of STI diagnosis and management [35]. These include rapid, point-of-care tests for HIV and syphilis that have been adopted and scaled up in many antenatal clinic settings and more recently, molecular assays for the diagnosis of CT, NG, and TV [36–38]. These new tests hold considerable promise for LMICs [39–41].
As with any health technology, it is crucial to consider any clinical benefits of point-of-care testing and treatment for STIs in pregnancy along with the associated costs of implementation and scale-up. This is especially important for LMICs that need to prioritise investment across a range of diagnostic technologies, treatments, and diseases within a relatively small fiscal space [42]. For these countries, there is considerable interest in weighing up the potential savings associated with the rapid delivery of results, reduced loss-to-follow-up and reduction of facility costs versus the long-run benefits associated with a laboratory confirmed diagnosis [43]. A new landscape for diagnostics is emerging in LMICs [37, 41, 44] and understanding the resource implications [45] and equity impact [46–48] on the health system and patients is a priority for policymakers [49]. To date, there have been no systematic reviews of the economic evidence relating to point-of-care testing and treatment for STIs in pregnancy. Consolidation and appraisal of studies in this field is timely and necessary for formulating strategies to achieve Sustainable Development Goal (SDG) 3: ensuring good health and well-being [50]. SDG 3 includes ending preventable deaths of newborns and children under 5 years of age and ensuring universal access to sexual and reproductive healthcare services [50, 51]. This systematic review examines economic evaluations of point-of-care testing and treatment of the most burdensome, curable STIs in pregnancy in LMICs. The specific objectives of this review are to:
- Identify and synthesise the evidence from economic evaluations of point-of-care testing and treatment for STIs in pregnancy in LMICs;
- Compare and contrast the findings, including key drivers of costs and cost-effectiveness; and
- Appraise methodological and reporting quality using the Drummond 10 point checklist [52] and the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) checklist [53].
Materials and methods
The methods for this review follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 File). The methodology summarised below adheres to the published systematic review protocol [54]. The review is registered in PROSPERO (CRD42018109072).
Literature search and study selection
A comprehensive literature search was conducted by two researchers (OPMS and NB) in MEDLINE, Embase, and Web of Science and completed in April 2020. The search terms, shown in Table 2, were developed with the help of medical librarians to ensure a sensitive search specific to the objectives of the systematic review. All database searches were identical. Keywords and MeSH terms framed the searches, while truncation was used to capture multiple terms and the Boolean operators “OR” and “AND” to combine sub-heading search terms. Thereafter, a simplified version of the search was conducted in Google Scholar and restricted to the first 100 citations. Finally, a hand search of the bibliographies of the articles selected for full text review was conducted.
Two researchers independently conducted the database searches, screened records, titles and abstracts using Microsoft Excel (version 365), read full texts, and hand searched references of the included articles (OPMS and NB). The full texts were independently assessed against the eligibility criteria. A third senior researcher resolved any disagreements (VW).
Studies were included in this review if they:
- conducted a full economic evaluation (comparing the costs and consequences of two or more options and include cost effectiveness analyses (CEAs), cost utility analyses (CUAs), cost-benefit analyses, or cost consequence analyses [55]) or a partial economic evaluation (measuring program or disease costs without comparisons with alternative options or outcomes [55]) of a point-of-care testing and treatment intervention for syphilis, NG, CT, TV or BV;
- focused on pregnant women;
- took place in at least one LMIC, as defined by the World Bank [56]; and
- were full papers published in a peer-reviewed journal (commentaries, conference abstracts, editorials, protocols, and review papers were excluded).
No publication date nor language filter was applied.
Data extraction and analysis
Data were extracted into a form developed, using Microsoft Excel (version 365), specifically for this review. Variables extracted were guided by the categories in the CHEERS checklist and included: study setting; type of STI; type of economic evaluation; time horizon; type of testing and treatment intervention and comparator; study perspective; types of costs; measures of effectiveness and cost-effectiveness; and sensitivity analysis results.
Data extraction highlighted the significant methodological heterogeneity between studies in terms of interventions, study design, cost categories, and health outcomes. Consequently, neither a meta-analysis nor a sub-group meta-analysis was able to be performed as originally envisaged [54]. The analysis for this review was limited to a descriptive summary and narrative synthesis. This entailed the tabulation of study characteristics and a comprehensive assessment of relevant themes [57]. In addition, percentage differences were calculated to demonstrate a unitless relative difference and describe how cost-effective an intervention is. The percentage difference is calculated by finding the absolute difference in cost-effectiveness ratios dividing them by the average of the two values and multiplying this by 100. Percentage differences alongside cost-effectiveness decision rules and key outcomes emphasize between study heterogeneity. No additional statistical analyses were performed.
Study appraisal
Two checklists were used to appraise the methodological quality and reporting standards of the studies included in this review. Methodological quality was assessed using the 10 point, 13-criteria Drummond checklist [52] and reporting quality was appraised using the CHEERS checklist [53]. Together the checklists ensure reporting transparency and consistency of appraisal of the studies included in this systematic review and optimised their comparability across common themes. Each item on the checklist was assigned ‘Yes’, ‘No’ or ‘Unclear’ and where the checklist item was not applicable, ‘N/A’, was used. All studies included in this systematic review were independently appraised by two researchers (OPMS and NB). A third, senior, researcher (VW) resolved any disagreements.
Results
Search results
A total of 532 studies were identified after the initial search of the electronic databases. Sixteen studies fulfilled the inclusion criteria. The selection strategy is illustrated by the PRISMA flow diagram in Fig 1.
Tables 3 and 4 summarise the key results of this systematic review. All studies assessed antenatal point-of-care testing and treatment for syphilis [58–70], except for one that focused on CT [71]. Two studies that assessed syphilis also evaluated point-of-care testing and treatment for HIV in pregnant women [72, 73]. Most studies were conducted in Africa (n = 10) [58, 59, 61–64, 66, 70, 71, 73], while three were conducted in Latin and South America [67, 68, 72] and the remaining three involved cross-country comparisons [60, 65, 69]. Of the single country analyses, four countries were classified as low-income countries [63, 68, 70, 73] and seven as middle-income countries [59, 62, 64, 66, 67, 71, 72]. For the remaining multi-country studies, the majority of countries were middle-income countries [58, 60, 61, 65, 69].
Economic evaluations
Type of economic evaluation.
Economic evaluations were categorised as either partial or full evaluations Table 3 indicates that four studies were partial economic evaluations [60, 63, 64, 72]. The remaining 12 studies were full economic evaluations, which included two cost-consequence analyses [61, 73] and 10 CEAs [58, 59, 62, 65–71], seven of which were CUAs [58, 65–70].
Perspectives, costs, and outcomes.
Nine studies conducted an economic evaluation using trial data [59, 60, 63, 64, 66–69, 72], while seven studies utilised existing literature [58, 61, 62, 65, 70, 71, 73]. Ten studies took a provider perspective [58–60, 63–66, 69, 71, 72], three took a societal perspective [61, 68, 73] and three studies did not specify the perspective taken [62, 67, 70]. The most common types of costs measured were direct and indirect medical costs related to tests and/or treatment, staff time, and other consumables such as medical supplies. Patient costs were rarely captured (n = 4) due to a provider perspective being taken by most studies.
All studies in this review compared a point-of-care testing and treatment intervention against one or more comparators as shown by Fig 2. Four studies compared laboratory-based testing with a point-of-care testing and treatment strategy [60, 63, 67, 70]. Six studies compared point-of-care testing and treatment against multiple comparators including laboratory testing, another point-of-care test, mass drug administration (MDA), syndromic management and/or no screening program [59, 61, 62, 68, 69, 73].
MDA: Mass Drug Administration; POC: point-of-care.
Most cost-effectiveness studies found point-of-care testing and treatment more cost-effective compared to laboratory-based testing [62, 67, 68, 70], no screening [58, 65, 66] or syndromic management [71] as shown in Table 4. For the full economic evaluations (n = 12), a variety of effects were measured. Most studies measured effectiveness by estimating the number of cases of adverse outcomes averted, such as miscarriage, stillbirth, neonatal death and congenital syphilis [58, 61, 65–71, 73].
Three-quarters of the full economic evaluations (n = 9) calculated incremental cost effectiveness ratios (ICERs), typically defined as the incremental cost per disability adjusted life years (DALY) averted or the incremental cost per case averted/cured [35, 37–40, 42, 43, 45, 46]. The ICERs reported varied considerably due to the heterogeneity of methods used to derive cost-effectiveness; therefore, making comparability difficult. The percentage differences emphasise the heterogeneity between studies included in this review. The greatest percentage difference between comparators was 170.6% (Cost/DALY of 63.1 and 5), while the smallest was 19.2% (Cost/DALY of 17 and 11.8).
Nine studies indicated a time horizon; the time horizon was typically restricted to 12 months or less [59, 63, 64, 66, 71, 72]. Only three studies modelled lifetime costs and effects of point-of-care testing and treatment for STIs in pregnancy on mothers and babies [61, 62, 73]. These studies did not explicitly indicate whether cost-effectiveness or outcomes were sustained over time.
Key drivers of economic evaluations
A sensitivity analysis was performed in 14 studies (87.5%) by varying key assumptions and recording the impact this had on the findings of the evaluation. Ten studies conducted a univariate sensitivity analysis and of those studies, six conducted a multivariate sensitivity analysis [59, 61, 63, 64, 68, 73] and three conducted a probabilistic sensitivity analysis [58, 69, 71] in addition to the univariate sensitivity analysis. The main drivers for costs and cost effectiveness are illustrated in Table 4 and included: STI prevalence [58, 59, 65–69, 71, 73], cost of test, cost of treatment, cost of training or salaries and wages [58, 61, 62, 64, 66–69, 71], test sensitivity and specificity [58, 59, 61, 62, 68, 70, 71], and treatment and/or screening coverage [63, 64, 66, 69, 73].
Quality appraisal
All studies met 75% or more of the methodology criteria of the Drummond Checklist and 60% for the CHEERS checklist (Fig 3). Fig 3 illustrates the shortcomings with respect to reporting criteria in the reviewed papers. The appraisal based on the Drummond checklist (Table 5), indicated that a key gap was the reporting of all relevant costs with few studies taking account of training, quality control and quality assurance. The appraisal using the CHEERS checklist (Table 6) highlighted that only half the studies (n = 8) clearly outlined the time horizon for the analysis [59, 61–64, 66, 71, 72], most taking a one year or shorter time horizon [59, 63, 64, 66, 71, 72]. Half the studies (n = 8) utilised analytical methods to deal with missing values and uncertainty [58, 61, 63, 65, 67, 68, 70, 71]. Only a third of the studies (n = 6) explained variations in the data by different population characteristics [60, 64, 67, 70–72]. The most common sub-group analyses were by type or location of health facility (hospital or health centre and urban or rural).
Discussion
This review identified 16 economic evaluations set in LMIC on point-of-care testing and treatment for STIs in pregnancy and presented a synthesis of the evidence. All but one study focused on syphilis and most were set in African countries. The majority of studies in this review suggest that point-of-care testing and treatment for syphilis and CT in pregnancy can be cost-effective in LMIC settings when compared to no screening programs, laboratory-based testing and/or syndromic management. These studies also indicate that point-of-care testing and treatment for STIs is most cost-effective where access to alternative testing mechanisms is limited, including laboratory testing facilities. Further, there was considerable variation in the types of costs and outcomes utilised by economic evaluations, as well as in the time horizons and sample sizes, which proved to be a challenge in comparing the costs and cost effectiveness of interventions across the different settings. The decision rules for cost-effectiveness and percentage differences in Table 4 demonstrate the between study variation. The decision rules indicate that cost-effectiveness is dependent upon the decision rule utilised. Further, percentage difference highlights the difference between the largest and smallest cost-effectiveness measures per study. The largest percentage difference between comparators was 170% [69] while the smallest 19% [70], which demonstrates the large variability with respect to measures of cost-effectiveness. Key drivers of cost and cost-effectiveness were STI prevalence and costs (including the cost of tests, treatment, training costs, and salaries or wages.
Our review also highlighted some gaps in the evidence, in terms of methodology and scope. First, the evidence is limited both in geographic and infection scope. Most studies were conducted on the African continent, with only one study conducted in Asia [65] and none in the Pacific. Further, point-of-care testing and treatment for syphilis in pregnancy dominated the literature. Only one economic evaluation focussed on CT and there were no economic evaluations of other prevalent, curable STIs such as NG, TV or BV. The lack of studies from Asia-Pacific countries is of concern given the high STI prevalence, particularly for common infections including syphilis, NG, TV, CT, reported among pregnant women in the region [68, 72, 75] as well as the widespread integration of point-of-care testing and treatment for syphilis in antenatal clinics [22]. Although existing economic evaluations provide guidance to cost-effectiveness, context matters. In particular, results from economic evaluations cannot always be generalised because local disease epidemiology, social, cultural and financial barriers to implementation vary between settings [76]. These could lead to differences in the uptake of testing and treatment between settings, and therefore, also differences in the cost of scale up.
In the last decade, the number of studies based in LMICs evaluating the utility of point-of-care tests for the detection and treatment of STIs in pregnancy has increased [38, 77], which has influenced the number of economic evaluations conducted on these types of tests. Yet with few cheap, accurate and easy to use point-of-care tests for CT, NG, TV and BV available [78], there have not been many effectiveness trials conducted in LMIC. As such, the data available to conduct robust economic evaluations is limited. Therefore, there is a need to expand the scope of effectiveness studies and accompanying economic evaluations of point-of-care testing for high-burden STIs in pregnancy [38, 79, 80].
Second, most studies included in this review took the provider perspective. Only three studies took a societal perspective. The paucity of studies conducted from the societal perspective potentially excludes and/or underestimates the direct and indirect costs to women such as reducing patient waiting times and reducing the number of clinic visits required to receive results, which in turn is expected to reduce the considerable direct and indirect costs incurred by many women seeking antenatal care in LMICs [81, 82]. Consequently, these direct and indirect costs can be, in many settings, barriers to participation as costs are often borne to the patient as OOP expenses and can lead to catastrophic health expenditure, which might lead to a drop in uptake/participation.
Third, most economic evaluations reviewed had short time horizons of 12 months or less. Short time horizons do not consider the lifetime implications of effective point-of-care testing and treatment of STIs in pregnancy. Economic evaluations in this field should ideally incorporate the long-term costs and benefits to both mother and baby from adopting point-of-care testing in order to capture said costs and benefits that occur later in life.
Our review indicated that all but two studies conducted a sensitivity analysis, which demonstrate the variables that drive costs and cost-effectiveness in each study. The most common drivers of cost and cost-effectiveness were STI prevalence and costs (which included the cost of tests, treatment, training costs, and salaries or wages). The sensitivity analyses of the studies included in this review did not explore the potential variation in loss-to-follow-up. These findings are consistent with other systematic reviews that have indicated that HIV prevalence and the cost of the HIV test are key drivers of cost-effectiveness of HIV screening in pregnancy [83] and key populations, such as sex workers [84].
We also found that most studies applied a narrow definition to the costs of point-of-care testing including only the cost of test kits, treatment costs and staff salaries. Costs associated with other core activities such as quality control, quality assurance and procurement are not negligible, and thus these studies may have underestimated the true cost of POC testing [85]. Underestimating costs leads to inaccurate projected costs for implementation and scale up, which consequently means that insufficient budget will be allocated to the implementation and scale up of the intervention. Insufficient funding, will inevitably mean that scale up will not go as planned, may be suspended, or may not run successfully [45]. Standardising the methodology, or introducing guidelines, for measuring costs may mitigate the likelihood that crucial costs are excluded from analyses. In addition, this will aid the comparison of costs across studies, which was particularly difficult in this review.
Finally, increased attention should also be paid to the broader issues of affordability and equity. Despite recent recommendations by the International Society for Pharmacoeconomics and Outcomes Research to conduct budget impact analyses alongside economic evaluations [45], no studies in this review did so although two did mention its importance [58, 62]. Budget impact analyses explore economic and financial consequences highlighting the affordability of program implementation. They specifically factor in short-run costs to cater for government budget allocations [45, 86] and are especially relevant in settings where health care resources are highly constrained [49]. There have been ongoing calls for incorporating equity within economic evaluations of health interventions [46, 48]. This is particularly relevant for point-of-care testing and treatment, which can reduce inequalities in healthcare by diagnosing and treating STIs in a single visit to a health facility. This is important in populations with limited access to laboratory facilities [87]. Future studies in this field should explore ways to expand cost-effectiveness analysis to address health equity concerns including distributional cost-effectiveness analysis which quantifies the distribution of costs and effects by equity-relevant variables such as socioeconomic status, location, ethnicity, sex and severity of illness [88]. Alternatively, non-health benefits such as financial risk protection could be measured using extended cost-effectiveness analysis [47, 89].
Economic evaluations generate evidence to optimally allocate resources and provide the foundation for the delivery of healthcare interventions [55]. This review has highlighted that point-of-care testing for STIs in pregnancy has proven to be cost effective in African settings. The results may be generalisable to similar settings, however consideration should be taken with the shortcomings revealed by this review, including the heterogenous nature of economic evaluations, the perspective taken and the short run time horizons. Suggesting that evidence should be interpreted with caution, and an economic evaluation conducted prior to implementing programmes to fill these gaps and provide better information to aid uptake, scale up and indicate priority settings in resource constrained contexts. Going forward, extended cost-effectiveness analyses and budget impact analyses provide evidence for the implementation of a cost-effective intervention, which is equitable, affordable, and sustainable. Extended cost-effectiveness analyses highlight the distributional effects within a given populations as a result of the implementation of an intervention; while budget impact analyses determine the investment required by the government to implement an intervention; and demonstrate affordability given available resources and budget constraints.
This review has some limitations, with respect to the synthesis of key results, the significant variability in economic methods, particularly regarding the types of costs and outcomes measured, meant that the planned meta-analysis was not possible [54]. Further, few studies utilised a societal perspective to determine costs, which may have understated the true value associated with point-of-care testing and treatment for STIs in pregnancy. However, the descriptive and narrative synthesis provides valuable insight into these limitations and gaps and suggests direction for future research. Additionally, most studies took a narrow view of costs and measured them along a short-run time horizon, which highlights a short-coming of the studies included in this review. This systematic review did not include grey literature, which can also be an important source of evidence but less likely to be subject to independent scientific peer-review, where additional bias is introduced. Finally, a further enhancement of economic evaluations would be the inclusion of equity and affordability analyses.
Conclusion
Our review indicates that point-of-care testing and treatment for syphilis in pregnancy is cost-effective in LMICs compared to laboratory-based testing, syndromic management and where no testing programs have been implemented. The review also revealed that key drivers of cost and cost-effectiveness are STI prevalence and costs (including the cost of tests, treatment, training costs, and salaries or wages. It also highlights important gaps in the published literature that requires urgent attention by researchers. These gaps include broadening the scope of economic evaluations to include common curable STIs, such as CT, NG, TV and BV; the geographical representation of studies; the costs borne to pregnant women and their families as a result of accessing testing and treatment for STIs; the life time costs and effects of testing and treatment on mothers and their babies and finally; the budget and equity implications of implementing point-of-care testing and treatment versus other screening practices.
Supporting information
S1 File. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.
https://doi.org/10.1371/journal.pone.0253135.s001
(DOCX)
References
- 1. Adachi K., Nielsen-Saines K., and Klausner J.D., Chlamydia trachomatis Infection in Pregnancy: The Global Challenge of Preventing Adverse Pregnancy and Infant Outcomes in Sub-Saharan Africa and Asia. Biomed Res Int., 2016. 2016: p. 21. pmid:27144177
- 2. Saleska J.L., et al., Use of Antiretroviral Therapy During Pregnancy and Adverse Birth Outcomes Among Women Living With HIV-1 in Low- and Middle-Income Countries: A Systematic Review. J Acquir Immune Defic Syndr, 2018. 79(1): p. 1–9. pmid:29847475
- 3. Shava E., et al., High rates of adverse birth outcomes in HIV and syphilis co-infected women in Botswana. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2019: p. 1.
- 4. Newman L., et al., Global Estimates of Syphilis in Pregnancy and Associated Adverse Outcomes: Analysis of Multinational Antenatal Surveillance Data. PLOS Medicine, 2013. 10(2): p. e1001396. pmid:23468598
- 5. Dingens A.S., et al., Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC pregnancy and childbirth, 2016. 16(1): p. 278–278. pmid:27658456
- 6. Olaleye A.O., et al., Sexually transmitted infections in pregnancy–An update on Chlamydia trachomatis and Neisseria gonorrhoeae. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2020. 255: p. 1–12. pmid:33059307
- 7. Olson-Chen C., Balaram K., and Hackney D.N., Chlamydia trachomatis and Adverse Pregnancy Outcomes: Meta-analysis of Patients With and Without Infection. Maternal and Child Health Journal, 2018. 22(6): p. 812–821. pmid:29417367
- 8. Konadu D.G., et al., Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. BMC Pregnancy and Childbirth, 2019. 19(1): p. 341. pmid:31547803
- 9. Vallely L.M., et al., Adverse pregnancy and neonatal outcomes associated with <em>Neisseria gonorrhoeae, Mycoplasma genitalium, M. hominis, Ureaplasma urealyticum and U. parvum:</em> a systematic review and meta-analysis protocol. BMJ Open, 2018. 8(11): p. e024175. pmid:30498048
- 10. Korenromp E.L., et al., Global burden of maternal and congenital syphilis and associated adverse birth outcomes—Estimates for 2016 and progress since 2012. PLOS ONE, 2019. 14(2): p. e0211720. pmid:30811406
- 11. Joseph Davey D.L., et al., Prevalence of Curable Sexually Transmitted Infections in Pregnant Women in Low- and Middle-Income Countries From 2010 to 2015: A Systematic Review. Sexually transmitted diseases, 2016. 43(7): p. 450–458. pmid:27322048
- 12.
WHO, Sexually Transmitted Infections (STIs): The importance of a renewed commitment to STI prevention and control in achieving global sexual and reproductive health. 2012, WHO: Geneva, Switzerland. p. 8.
- 13. Mullick S., et al., Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sexually Transmitted Infections, 2005. 81(4): p. 294–302. pmid:16061534
- 14. Rowley J., et al., Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ, 2019. 97(8): p. 548–562p. pmid:31384073
- 15. Gomez G.B., et al., Untreated maternal syphilis and adverse outcomes of pregnancy: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2013. 91(3): p. 217–226. pmid:23476094
- 16. Johnson H.L., et al., Sexually Transmitted Infections and Adverse Pregnancy Outcomes Among Women Attending Inner City Public Sexually Transmitted Diseases Clinics. Sexually Transmitted Diseases, 2011. 38(3): p. 167–171. pmid:20852454
- 17. Hawkes S, M.N., Broutet N, Low N, Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis Lancet Infect Dis, 2011. 11(9): p. 684–91. pmid:21683653
- 18. Moodley T., et al., Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. BMC Pregnancy and Childbirth, 2016. 16(1): p. 35. pmid:26867536
- 19. Chagomerana M.B., et al., Optimizing prevention of HIV mother to child transmission: Duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women. PLOS ONE, 2018. 13(4): p. e0195033. pmid:29614083
- 20. Swartzendruber A., et al., Introduction of rapid syphilis testing in antenatal care: A systematic review of the impact on HIV and syphilis testing uptake and coverage. International Journal of Gynaecology & Obstetrics, 2015. 130 Suppl 1: p. S15–21. pmid:26001704
- 21.
WHO, Pregnancy, childbirth, postpartum and newborn care: a guide for essential practice. 2015, WHO. p. 184.
- 22.
WHO, WHO Guideline on: Syphilis screening and treatment for pregnant women. 2017, WHO.
- 23.
WHO WHO recommendation on sexually transmitted infections testing in pregnancy. 2016, WHO: Geneva.
- 24.
World Health Organization. Regional Office for the Western, P., Regional framework for the triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis in Asia and the Pacific, 2018–2030. 2018: Manila: WHO Regional Office for the Western Pacific.
- 25.
WHO, Sexually transmitted and other reproductive tract infections. 2005: Geneva.
- 26. Moodley D., et al., High Prevalence and Incidence of Asymptomatic Sexually Transmitted Infections During Pregnancy and Postdelivery in KwaZulu Natal, South Africa. Sexually Transmitted Diseases, 2015. 42(1). pmid:25504300
- 27. Kaida A., et al., A high burden of asymptomatic genital tract infections undermines the syndromic management approach among adolescents and young adults in South Africa: implications for HIV prevention efforts. BMC Infectious Diseases, 2018. 18(1): p. 499. pmid:30285705
- 28. Garrett N.J., McGrath N., and Mindel A., Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? Sexually Transmitted Infections, 2017. 93(1): p. 4–5. pmid:27084840
- 29. Herring A., et al., Evaluation of rapid diagnostic tests: syphilis. Nature Reviews Microbiology, 2006. 4(12): p. S33–S40. pmid:17366685
- 30. Peeling R. and Ye H., Peeling R. W. & Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. Bull. World Health Organ. 82, 439–446. Bulletin of the World Health Organization, 2004. 82: p. 439–46. pmid:15356937
- 31. Cristillo A.D., et al., Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. Sexually Transmitted Diseases, 2017. 44(4): p. 211–218. pmid:28282646
- 32.
WHO, Guidelines for the management of sexually transmitted infections. 2003, WHO. https://doi.org/10.1136/sti.79.2.111 pmid:12690130
- 33.
WHO, Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus, Magnus Unemo R.B., Catherine Ison, David Lewis, Francis Ndowa, Rosanna Peeling, Editor. 2013, WHO: Geneva.
- 34. WHO. Point-Of-Care Diagnostic Tests (POCTs) for Sexually Transmitted Infections (STIs). 2018 19/11/2018]; Available from: https://www.who.int/reproductivehealth/topics/rtis/pocts/en/.
- 35. Peeling R.W. and Mabey D., Point-of-care tests for diagnosing infections in the developing world. Clinical Microbiology & Infection, 2010. 16(8): p. 1062–9. pmid:20670288
- 36. Guy R.J., et al., Molecular point-of-care testing for chlamydia and gonorrhoea in Indigenous Australians attending remote primary health services (TTANGO): a cluster-randomised, controlled, crossover trial. The Lancet Infectious Diseases, 2018. 18(10): p. 1117–1126. pmid:30303108
- 37. Morris S.R., et al., Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. Lancet Infect Dis, 2020. pmid:33242473
- 38. Badman S.G., et al., A novel point-of-care testing strategy for sexually transmitted infections among pregnant women in high-burden settings: results of a feasibility study in Papua New Guinea. BMC infectious diseases, 2016. 16: p. 250–250. pmid:27268218
- 39. Mabey D.C., et al., Point-of-Care Tests to Strengthen Health Systems and Save Newborn Lives: The Case of Syphilis. PLOS Medicine, 2012. 9(6): p. e1001233. pmid:22719229
- 40. Marks M. and Mabey D.C., The introduction of syphilis point of care tests in resource limited settings. Expert review of molecular diagnostics, 2017. 17(4): p. 321–325. pmid:28266230
- 41. Gaydos C.A., et al., Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. Journal of clinical microbiology, 2013. 51(6): p. 1666–1672. pmid:23467600
- 42. Heller P.S., The prospects of creating ’fiscal space’ for the health sector. Health Policy Plan, 2006. 21(2): p. 75–9. pmid:16415338
- 43. Fleming K.A., et al., An Essential Pathology Package for Low- and Middle-Income Countries. American Journal of Clinical Pathology, 2017. 147(1): p. 15–32. pmid:28158414
- 44. Toliman P., et al., Field Evaluation of Xpert HPV Point-of-Care Test for Detection of Human Papillomavirus Infection by Use of Self-Collected Vaginal and Clinician-Collected Cervical Specimens. Journal of clinical microbiology, 2016. 54(7): p. 1734–1737. pmid:27076663
- 45. Bilinski A., et al., When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs. PLOS Medicine, 2017. 14(10): p. e1002397. pmid:28968399
- 46. Cookson R., et al., Health equity monitoring for healthcare quality assurance. Social Science & Medicine, 2018. 198: p. 148–156. pmid:29335161
- 47. Verguet S., Kim J.J., and Jamison D.T., Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics, 2016. 34(9): p. 913–923. pmid:27374172
- 48. Cookson R., et al., Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017. 20(2): p. 206–212. pmid:28237196
- 49. Wiseman V., et al., Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks. Health Economics, 2016. 25(S1): p. 140–161. pmid:26804361
- 50. UNDP, Transforming our world: the 2030 agenda for sustainable development. 2015.
- 51. St John A. and Price C.P., Economic Evidence and Point-of-Care Testing. The Clinical biochemist. Reviews, 2013. 34(2): p. 61–74. pmid:24151342
- 52. Drummond M.F. and Jefferson T.O., Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (Clinical research ed.), 1996. 313(7052): p. 275–283. pmid:8704542
- 53. Husereau D., et al., Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value in Health, 2013. 16(2): p. 231–250. pmid:23538175
- 54. Saweri O.P.M., et al., Cost and cost-effectiveness of point-of-care testing and treatment for sexually transmitted and genital infections in pregnancy in low-income and middle-income countries: a systematic review protocol. BMJ Open, 2019. 9(11): p. e029945. pmid:31727649
- 55.
Drummond M.F., et al., Methods for the Economic Evaluation of Health Care Programmes. 1997, Oxford: Oxford University Press.
- 56. The World Bank Group. Low and Middle Income Country Classification. 2018 19/11/2018]; Available from: https://data.worldbank.org/income-level/low-and-middle-income?view=chart.
- 57. Ryan R; Cochrane Consumers and Communication Review Group. Data synthesis and analysis. 2013 [cited June 2013 4th March 2020]; Available from: https://cccrg.cochrane.org/sites/cccrg.cochrane.org/files/public/uploads/AnalysisRestyled.pdf.
- 58. Kuznik A., et al., Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis. PLoS Medicine / Public Library of Science, 2013. 10(11): p. e1001545. pmid:24223524
- 59. Blandford J.M., et al., Cost-effectiveness of on-site antenatal screening to prevent congenital syphilis in rural eastern Cape Province, Republic of South Africa. Sexually Transmitted Diseases, 2007. 34(7 Suppl): p. S61–6. pmid:17308502
- 60. Levin C.E., et al., Analysis of the operational costs of using rapid syphilis tests for the detection of maternal syphilis in Bolivia and Mozambique. Sexually Transmitted Diseases, 2007. 34(7 Suppl): p. S47–54. pmid:17220812
- 61. Owusu-Edusei K. Jr, Gift T.L., and Ballard R.C., Cost-effectiveness of a dual non-treponemal/treponemal syphilis point-of-care test to prevent adverse pregnancy outcomes in Sub-Saharan Africa. Sexually Transmitted Diseases, 2011. 38(11): p. 997–1003. pmid:21992974
- 62. Rydzak C.E. and Goldie S.J., Cost-effectiveness of rapid point-of-care prenatal syphilis screening in sub-Saharan Africa. Sexually Transmitted Diseases, 2008. 35(9): p. 775–784. pmid:18607319
- 63. Sweeney S., et al., The costs of accessible quality assured syphilis diagnostics: informing quality systems for rapid syphilis tests in a Tanzanian setting. Health policy and planning, 2014. 29(5): p. 633–641. pmid:23894075
- 64. Shelley K.D., et al., Scaling Down to Scale Up: A Health Economic Analysis of Integrating Point-of-Care Syphilis Testing into Antenatal Care in Zambia during Pilot and National Rollout Implementation. Plos One, 2015. 10(5): p. 19. pmid:25970443
- 65. Kuznik A., et al., Antenatal syphilis screening using point-of-care testing in low- and middle-income countries in Asia and Latin America: a cost-effectiveness analysis. PLoS ONE [Electronic Resource], 2015. 10(5): p. e0127379. pmid:26010366
- 66. Larson B.A., et al., Finding a needle in the haystack: the costs and cost-effectiveness of syphilis diagnosis and treatment during pregnancy to prevent congenital syphilis in Kalomo District of Zambia. PLoS ONE [Electronic Resource], 2014. 9(12): p. e113868. pmid:25478877
- 67. Mallma P., et al., Rapid Syphilis Testing Is Cost-Effective Even in Low-Prevalence Settings: The CISNE-PERU Experience. Plos One, 2016. 11(3): p. 11. pmid:26949941
- 68. Schackman B.R., et al., Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Medicine / Public Library of Science, 2007. 4(5): p. e183.
- 69. Terris-Prestholt F., et al., The cost-effectiveness of 10 antenatal syphilis screening and treatment approaches in Peru, Tanzania, and Zambia. International Journal of Gynecology and Obstetrics, 2015. 130(S1): p. S73–S80.
- 70. Vickerman P., et al., Modelling the cost-effectiveness of introducing rapid syphilis tests into an antenatal syphilis screening programme in Mwanza, Tanzania. Sexually Transmitted Infections, 2006. 82 Suppl 5: p. v38–43. pmid:17215276
- 71. Romoren M., et al., Costs and health consequences of chlamydia management strategies among pregnant women in sub-Saharan Africa. Sexually Transmitted Infections, 2007. 83(7): p. 558–66. pmid:17932126
- 72. Obure C.D., et al., A comparative analysis of costs of single and dual rapid HIV and syphilis diagnostics: Results from a randomised controlled trial in Colombia. Sexually Transmitted Infections, 2017. 93(7): p. 482–486. pmid:28495681
- 73. Bristow C.C., et al., Cost-effectiveness of HIV and syphilis antenatal screening: a modelling study. Sex Transm Infect, 2016. 92(5): p. 340–6. pmid:26920867
- 74. Romoren M., et al., Chlamydia and gonorrhoea in pregnant Batswana women: time to discard the syndromic approach? BMC infectious diseases, 2007. 7: p. 27–27. pmid:17437632
- 75. Vallely A., et al., The prevalence of sexually transmitted infections in Papua New Guinea: a systematic review and meta-analysis. PloS one, 2010. 5(12): p. e15586–e15586. pmid:21203468
- 76. Hutubessy R., Chisholm D., and Edejer T.T., Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc, 2003. 1(1): p. 8. pmid:14687420
- 77. Phang Romero Casas C., et al., Rapid diagnostic test for antenatal syphilis screening in low-income and middle-income countries: a systematic review and meta-analysis. BMJ Open, 2018. 8(2): p. e018132. pmid:29467132
- 78. Gaydos C. and Hardick J., Point of care diagnostics for sexually transmitted infections: perspectives and advances. Expert review of anti-infective therapy, 2014. 12(6): p. 657–672. pmid:24484215
- 79. Causer L.M., et al., Molecular test for chlamydia and gonorrhoea used at point of care in remote primary healthcare settings: a diagnostic test evaluation. Sexually Transmitted Infections, 2018. 94(5): p. 340–345. pmid:29748180
- 80. Gadoth A., et al., Prenatal chlamydial, gonococcal, and trichomonal screening in the Democratic Republic of Congo for case detection and management. International Journal of STD & AIDS, 2020. 31(3): p. 221–229.
- 81. Byford S. and Raftery J., Perspectives in economic evaluation. 1998. 316(7143): p. 1529–1530.
- 82. Jönsson B.J.T.E.J.o.H.E., Ten arguments for a societal perspective in the economic evaluation of medical innovations. 2009. 10(4): p. 357–359.
- 83. Bert F., et al., HIV screening in pregnant women: A systematic review of cost-effectiveness studies. Int J Health Plann Manage, 2018. 33(1): p. 31–50. pmid:28556453
- 84. Rinaldi G., Kiadaliri A.A., and Haghparast-Bidgoli H., Cost effectiveness of HIV and sexual reproductive health interventions targeting sex workers: a systematic review. Cost Effectiveness and Resource Allocation, 2018. 16(1): p. 63. pmid:30524207
- 85. Drain P.K., et al., Diagnostic point-of-care tests in resource-limited settings. The Lancet. Infectious diseases, 2014. 14(3): p. 239–249. pmid:24332389
- 86. Sullivan S.D., et al., Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health, 2014. 17(1): p. 5–14. pmid:24438712
- 87. Peeling R.W., Applying new technologies for diagnosing sexually transmitted infections in resource-poor settings. Sexually Transmitted Infections, 2011. 87 Suppl 2: p. ii28-30. pmid:22110150
- 88. Verguet S., et al., Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine, 2013. 31(42): p. 4902–4910. pmid:23871824
- 89. Verguet S., et al., Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. The Lancet Global Health, 2015. 3(5): p. e288–e296. pmid:25889470